Abstract
The agonist profiles for Ca++ elevations mediated by the human alpha-2 adrenoceptor subtypes alpha-2A,alpha-2B and alpha-2C were compared in the clones of Chinese hamster ovary cells expressing comparable numbers of receptors. No difference was seen between the different clones with respect to the maximum Ca++ mobilizations or the concentrations producing half-maximal stimulation in response to noradrenaline. Ca++ elevations were sensitive to phospholipase C inhibitor U-73122 (1-[6-([17β]-3-methoxyestra-1,3,5[10]-trien-17-yl)aminohexyl]-1H-pyrrole-2,5-dione) and pertussis toxin-pretreatment. Although noradrenaline was equally potent and active in all the clones, marked differences in the response to the other agonists were seen. UK14,304 (5-bromo-N-[4,5-dihydro-1H-imidazol-2-yl]-6-quinoxalinamine) was a full agonist (when compared to noradrenaline) for alpha-2A and alpha-2C, d-medetomidine ([+]-[S]-[4-(1-[2,3-dimethylphenyl]ethyl)-1H-imidazole]HCl) was a full agonist for alpha-2B and alpha-2C and oxymetazoline (3-[(4,5-dihydro-1H-imidazol-2-yl-)methyl]-6-[1,1-dimethylethyl]-2,4-dimethylphenol HCl) was a full agonist only for alpha-2B receptors. Clonidine (2-[2,6-dichloroaniline]-2-imidazoline HCl) was a partial agonist in all the cases; almost no response to this ligand was obtained in the alpha-2B-expressing cells. When the Ca++ responses are compared to the previously published results on cAMP inhibition in Chinese hamster ovary cells, clonidine seems to be significantly less efficacious in elevating Ca++ than in decreasing cAMP.
Footnotes
-
Send reprint requests to: Dr. Jyrki Kukkonen, Department of Physiology, Uppsala University, BMC, P.O. Box 572, S-75123 Uppsala, Sweden.
-
↵1 This study was supported by The Technology Development Center of Finland, The Magnus Ehrnrooth Foundation, The Medical Research Council of Sweden and The Cancer Research Fund of Sweden.
- Abbreviations:
- [Ca++]i
- intracellular free [Ca++]
- CHO
- Chinese hamster ovary
- clonidine
- 2-(2,6-dichloroaniline)-2-imidazoline HCl
- Δ[Ca++]
- elevation of intracellular free [Ca++] (= [Ca++]i/stimulated − [Ca++]i/basal)
- Δ[Ca++]max
- maximum elevation of intracellular free [Ca++]
- d-medetomidine
- [+]-[S]-(4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole)HCl
- EC50
- concentration producing half-maximal response
- EGTA
- ethylene glycol-bis(β-aminoethyl ether) N,N,N′,N′-tetraacetic acid
- oxymetazoline
- 3-([4,5-dihydro-1H-imidazol-2-yl-]methyl)-6-(1,1-dimethylethyl)-2,4-dimethylphenol HCl
- probenecid
- p-(dipropylsulfamoyl)benzoic acid
- TBM
- TES buffered medium
- TES
- 2-([2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino) ethane sulfonic acid
- UK14
- 304, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine
- U-73122
- 1-(6-[(17β)-3-methoxyestra-1,3,5(10)-trien-17-yl]aminohexyl)-1H-pyrrole-2,5-dione
- U-73343
- 1-(6-[(17β)-3-methoxyestra-1,3,5(10)-trien-17-yl]aminohexyl)-2,5-dione
- Received March 30, 1998.
- Accepted June 23, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|